| Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney disease. | |
| | |
MedLine Citation:
|
PMID: 21956770 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Ferumoxytol is a new product approved for intravenous use by the US Food and Drug Administration (FDA) in the treatment of iron deficiency anemia in adults with chronic kidney disease. This approval was based on data from 3 open-label, randomized, controlled clinical trials. In all of these trials, ferumoxytol was well tolerated, and hemoglobin levels were significantly increased compared with those achieved by orally administered iron. Ferumoxytol, a superparamagnetic iron oxide coated with a carbohydrate shell, is also used as a magnetic resonance imaging (MRI) agent due to its magnetic properties. In addition, it has demonstrated a greater T1 relaxation time than MRI gadolinium-contrast agents. Currently, the Ferumoxytol Compared to Iron Sucrose Trial (FIRST) has started. This is a multicenter randomized trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in adult subjects with chronic kidney disease, where intravenous ferumoxytol is being compared with other intravenous agents to evaluate the safety of ferumoxytol and assess changes in hemoglobin level. |
| | |
Authors:
|
Mariusz Kowalczyk; Maciej Banach; Jacek Rysz |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Journal of nephrology Volume: 24 ISSN: 1724-6059 ISO Abbreviation: J. Nephrol. Publication Date: 2011 Nov-Dec |
Date Detail:
|
Created Date: 2011-11-07 Completed Date: 2012-04-18 Revised Date: 2012-04-27 |
Medline Journal Info:
|
Nlm Unique ID: 9012268 Medline TA: J Nephrol Country: Italy |
Other Details:
|
Languages: eng Pagination: 717-22 Citation Subset: IM |
Affiliation:
|
Department of Nephrology, Medical University of Lodz, Lodz, Poland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anemia, Iron-Deficiency
/
drug therapy*,
epidemiology*,
metabolism Chronic Disease Comorbidity Ferric Compounds / adverse effects, therapeutic use Ferumoxytol / adverse effects, therapeutic use* Hematinics / adverse effects, therapeutic use Hemoglobins / metabolism Humans Kidney Diseases / epidemiology*, metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Ferric Compounds; 0/Hematinics; 0/Hemoglobins; 1317-61-9/Ferumoxytol; 8047-67-4/ferric oxide, saccharated |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Outcomes of rationing dialysis therapy in biopsy-proven end-stage renal disease in South Africa.
Next Document: Effect of paricalcitol and GcMAF on angiogenesis and human peripheral blood mononuclear cell prolife...